Meta-analysis of infectious endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 45, Issue 2, 2014, Pages 143-149

  Fileta, John B ^a   Scott, Ingrid U ^a   Flynn Jr , Harry W ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; BACILLUS; BACTERIUM CULTURE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENDOPHTHALMITIS; ENTEROCOCCUS FAECALIS; HAEMOPHILUS; HUMAN; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; VISUAL ACUITY; INFECTIOUS ENDOPHTHALMITIS; OUTCOME ASSESSMENT; BACTERIAL EYE INFECTION; DRUG ANTAGONISM; INTRAVITREAL DRUG ADMINISTRATION; MICROBIOLOGY; RETINA DISEASE; RISK FACTOR;

ANGIOGENESIS INHIBITORS; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; HUMANS; INTRAVITREAL INJECTIONS; RETINAL DISEASES; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84898631546     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20140306-08     Document Type: Article

References (60)

1. Ramulu PY, Do DV, Corcoran KJ, Corcoran SL, Robin AL. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. Arch Ophthalmol. 2010;(128)1335-1340.
2. United States Senate Special Committee on Aging Statement of Jonathan Blum, Deputy Administrator and Director, Center for Medicare and Medicaid Services, on sustaining the Medicare program through lower costs, before the United States Senate Special Committee on Aging. July 21, 2011. http://aging.senate.gov/events/hr236jb.pdf Accessed May 7, 2012.
3. McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011;31(4):654-661.
4. Chen E, Lin MY, Cox J, Brown DM. Endophthalmitis after intravitreal injection: the importance of viridans streptococci. Retina. 2011;(8):1525-1533.
5. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;(246):81-87. (Pubitemid 350167096)
6. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina. 2009;29(5):601-605.
7. Moshfeghi AA, Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmitis after intravitreal anti-vascular endothelial growth factor antagonists: a six-year experience at a university referral center. Retina. 2011;31(4):662-668.
8. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of Endophthalmitis and Use of Antibiotic Prophylaxis after Intravitreal Injections. Ophthalmology. 2012;119(8):1609-1614.
9. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology. 2011;118(10):2028-2034.
10. Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266-272.
11. Mahajan VB, Elkins KA, Russell SR, et al. Bilateral intravitreal injection of antivascular endothelial growth factor therapy. Retina. 2011;31(1):31-35.
12. Fong DS, Custis P, Howes J, Hsu JW. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study. Ophthalmology 2010;(117):298-302.
13. Mezad-Koursh D, Goldstein M, Heilwail G, Zayit-Soudry S, Loewenstein A, Barak A. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor. Retina. 2010;30(7):1051-1057.
14. Bakri SJ, Risco M, Edwards AO, Pulido JS. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol. 2009;148(1):66-69.
15. Klein KS, Walsh MK, Hassan TS, et al. Endophthalmitis after anti-VEGF injections. Ophthalmology. 2009;(116):1225-1225e1.
16. Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009;(29):1213-1217.
17. Diago T, McCannel CA, Bakri SJ, Pulido JS, Edwards AO, Pach JM. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents. Retina. 2009;29(5):601-605.
18. Artunay O, Yuzbasioglu E, Rasier R, Sengül A, Bahcecioglu H. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye. 2009;23(12):2187-2193.
19. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;(28):1395-1399.
20. Pilli S, Kotsolis A, Spaide RF, et al. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879-882.
21. Mason JO III, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina. 2008;(28):564-567. (Pubitemid 351589565)
22. Arevalo JF, Fromow-Guerra J, Sanchez JG, et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Ret ina Study Group at 12 months follow-up. Retina. 2008;28(10):1387-1394.
23. Martin DF, Maguire MG, Fine SL, et al Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Writing Committee. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: Two-Year Results. Ophthalmology. 2012 Jul;119(7):1388-1398.
24. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
25. Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Bevacizumab for Macular Edema in Central Retinal Vein Occlusion: A Prospective, Randomized, Double-Masked Clinical Study. Ophthalmology. 2012;119(6):1184-1189.
26. Singer MA, Awh CC, Sadda S, et al. HORIZON: An Open-Label Extension Trial of Ranibizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Ophthalmology. 2012;119(6):1175-1183.
27. Do DV, Nguyen QD, Boyer D, et al DAVINCI Study Group. One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. Ophthalmology. 2012;119(8):1658-1665.
28. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al MONT BLANC Study Group. Verteporfin plus Ranibizumab for Choroidal Neovas cularization in Age-related Macular Degeneration: Twelve-month MONT BLANC Study Results. Ophthalmology. 2012;119(5):992-1000.
29. Boyer D, Heier J, Brown DM, et al. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion: Six-Month Results of the Phase 3 COPERNICUS Study. Ophthalmology. 2012;119(5):1024-1032.
30. Nguyen QD, Brown DM, Marcus DM, et al; RISE and RIDE Re search Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789-801.
31. Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular Edema: 24-Month Data: Report 3. Arch Ophthalmol. 2012;130(8):972-979.
32. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group. Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration: Twelve-Month Results of the DENALI Study. Ophthalmology. 2012;119(5):1001-1010.
33. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041- 2049.
34. Schmidt-Erfurth U, Eldem B, Guymer R, et al EXCITE Study Group. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology. 2011;118(5):831-839.
35. Heier JS, Boyer D, Nguyen QD, et al; CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular en dothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118(6):1098-1106.
36. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or com bined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615-625.
37. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150(3):315-324.
38. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145(2):239-248.
39. Elman MJ, Aiello LP, Beck RW, et al; Diabetic Retinopathy Clinical Research Network, Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-1077.
40. Campochiaro PA, Heier JS, Feiner L, BRAVO Investigators et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-1112.
41. Tufail A, Patel PJ, Egan C, et al ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multi centre randomised double masked study. Br Med J. 2010;(340):c2459.
42. Brown DM,MichelsM, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;(116):57-65.
43. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regi men with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.
44. Bhavsar AR, Googe JM Jr, Stockdale CR, et al Diabetic Retinopathy Clinical Research Network. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol. 2009;127(12):1581-1583.
45. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acu ity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147(2):298-306.
46. Scott IU, Edwards AR, Beck RW, et al Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intra vitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-1867.
47. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multi center, controlled, multidose study. Ophthalmology. 2006;(113):633-642.
48. Heier JS, Boyer DS, Ciulla TA, et al. FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovas cular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol. 2006;124(11):1532-1542. (Pubitemid 44748725)
49. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;(355):1419-1431. (Pubitemid 44511557)
50. Wen JC, McCannel CA, Mochon AB, Garner OB. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551-1554.
51. Lalwani GA, Flynn HW Jr, Scott IU, et al. Acute-onset endophthalmitis after clear corneal cataract surgery (1996-2005). Clinical fea tures, causative organisms, and visual acuity outcomes. Ophthalmology. 2008;(115):473-476.
52. Scott IU, Flynn HW Jr, Dev S, et al. Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: incidence and outcomes. Retina. 2008;(28):138-142.
53. The Endophthalmitis Vitrectomy Study Group. Microbiologic factors and visual outcome in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;(122):830-846.
54. Jacobs DJ, Leng T, Flynn HW Jr, Shi W, Miller D, Gedde SJ. Delayed-onset bleb-associated endophthalmitis: presentation and out come by culture result. Clin Ophthalmol. 2011;(5):739-744.
55. Leng T, Miller D, Flynn HW Jr, Jacobs DJ, Gedde SJ. Delayed-onset bleb-associated endophthalmitis (1996-2008): causative organisms and visual acuity outcomes. Retina. 2011;31(2):344-352.
56. Schimel AM, Scott IU, Flynn HW Jr. Endophthalmitis after intravitreal injections: should the use of face masks be the standard of care? Arch Ophthalmol. 2011;129(12):1607-1609.
57. Simunovic MP, Rush RB, Hunyor AP, Chang AA. Endophthalmitis following intravitreal injection versus endophthalmitis following cataract surgery: clinical features, causative organisms and posttreatment outcomes. Br J Ophthalmol. 2012;(96):862-866.
58. Agresti A, Coull BA. "Approximate is better than 'exact' for in terval estimation of binomial proportions." American Statistician. 1998;(52):119-126.
59. Liao, Tim Futing. "Odds Ratio." Encyclopedia of Social Science Research Methods. Ed. Michael S. Lewis-Beck, Alan Bryman, and Tim Futing Liao. Thousand Oaks, CA: SAGE Publications, Inc., 2004. 760-761. SAGE knowledge. 21 Nov. 2013.
60. Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities "hand motion" and "counting fingers" can be quanti fied with the Freiburg Visual Acuity Test. Invest Ophthalmol Vis Sci.